Ocular drug delivery

Expert Opinion on Drug Delivery

Volumn 3, Issue 2, 2006, Pages 275-287

  Ghate, Deepta ^a   Edelhauser, Henry F ^a  

^a EMORY EYE CENTER   (United States)

Author keywords

Intravitreal injection; Ocular drug delivery; Ocular pharmacokinetics; Posterior subtenon injection; Topical drug delivery

Indexed keywords

AMIKACIN; ANTIINFLAMMATORY AGENT; BENZALKONIUM CHLORIDE; BILE ACID; BILE SALT; CARBONATE DEHYDRATASE INHIBITOR; CARBOPLATIN; CEFAZOLIN; CHLORAMPHENICOL; CIPROFLOXACIN; CISPLATIN; CYCLODEXTRIN; CYCLOSPORIN A; DEXAMETHASONE; DIGITONIN; EYE DROPS; EYE OINTMENT; GATIFLOXACIN; INDOMETACIN; INULIN; MINOCYCLINE; NONIONIC SURFACTANT; OFLOXACIN; PILOCARPINE; PREDNISOLONE 21 PHOSPHATE; PREDNISOLONE ACETATE; SAPONIN; STEROID; TIMOLOL MALEATE; UNINDEXED DRUG;

BLOOD EYE BARRIER; BLOOD RETINA BARRIER; CORNEA EPITHELIUM; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG PENETRATION; DRUG TARGETING; DRUG TISSUE LEVEL; ENDOPHTHALMITIS; EYE DISEASE; GLAUCOMA; HUMAN; HYDROCOLLOID; IONTOPHORESIS; NONHUMAN; PATIENT COMPLIANCE; RETINA TUMOR; REVIEW; SURGICAL TECHNIQUE; UNSPECIFIED SIDE EFFECT; VISCOSITY;

ABSORPTION; ANIMALS; BLOOD-AQUEOUS BARRIER; DOSAGE FORMS; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; EYE; EYE DISEASES; HUMANS;

EID: 33644778489     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.3.2.275     Document Type: Review

References (116)

1. HANIOGLU-KARGI S, BASCI N, SOYSAL H, BOZKURT A, GURSEL E, KAYAALP O: The penetration of ofloxacin into human aqueous humor given by various routes. Eur. J. Ophthalmol. (1998) 8(1):33-36.
2. SCHOENWALD RW: Ocular pharmakokinetics. In: Textbook of Ocular Pharmacology. TJ Zimmerman (Ed.), Lippincott-Raven Publishers, PA, USA (1997):119-138.
3. WATSKY MA, JABLONSKI MM, EDELHAUSER HF: Comparison of conjunctival and corneal surface areas in rabbit and human. Curr. Eye Res. (1988) 7(5):483-486.
4. WILSON CG, ZHU YP, KURMALA P, RAO LS, DHILLON B: Ophthalmic drug delivery. In: Drug Delivery and Targeting for Pharmacists and Pharmaceutical Scientists. AM Hillery, AW Lloyd (Ed.), Taylor and Francis, New York, NY, USA (2001):329-354.
5. PRAUSNITZ MR, NOONAN JS: Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J. Pharm. Sci. (1998) 87(12):1479-1488.
6. LEIBOWITZ HM, KUPFERMAN A: Anti-inflammatory medications. Int. Ophthalmol. Clin. (1980) 20(3):117-134.
7. SOUSA FJ: The bioavailability and therapeutic effectiveness of prednisolone acetate vs. prednisolone sodium phosphate: a 20-year review. CLAO J. (1991) 17(4):282-284.
8. APT L, HENRICK A, SILVERMAN LM: Patient compliance with use of topical ophthalmic corticosteroid suspensions. Am. J. Ophthalmol. (1979) 87(2):210-214.
9. LEIBOWITZ HM, KUPFERMAN A: Kinetics of topically administered prednisolone acetate. Optimal concentration for treatment of inflammatory keratitis. Arch. Ophthalmol. (1976) 94(8):1387-1389.
10. LEIBOWITZ HM: Management of inflammation in the cornea and conjunctiva. Ophthalmology (1980) 87(8):753-758.
11. SCHOENWALD RD, STEWART P: Effect of particle size on ophthalmic bioavailability of dexamethasone suspensions in rabbits. J. Pharm. Sci. (1980) 69(4):391-394.
12. SIEG JW, ROBINSON JR: Vehicle effects on ocular drug bioavailability II: evaluation of pilocarpine. J. Pharm. Sci. (1977) 66(9):1222-1228.
13. KAUR IP, SMITHA R: Penetration enhancers and ocular bioadhesives: two new avenues for ophthalmic drug delivery. Drug Dev. Ind. Pharm. (2002) 28(4):353-369.
14. AKTAS Y, UNLU N, ORHAN M, IRKEC M, HINCAL AA: Influence of hydroxypropyl beta-cyclodextrin on the corneal permeation of pilocarpine. Drug Dev. Ind. Pharm. (2003) 29(2):223-230.
15. MAESTRELLI F, MURA P, CASINI A, MINCIONE F, SCOZZAFAVA A, SUPURAN CT: Cyclodextrin complexes of sulfonamide carbonic anhydrase inhibitors aslong-lasting topically acting antiglaucoma agents. J. Pharm. Sci. (2002) 91(10):2211-2219.
16. MITRA AK, MIKKELSON TJ: Mechanism of transcorneal permeation of pilocarpine. Pharm. Sci. (1988) 77(9):771-775.
17. BRECHUE WF, MAREN TH: pH and drug ionization affects ocular pressure lowering of topical carbonic anhydrase inhibitors. Invest. Ophthalmol. Vis. Sci. (1993) 34(8):2581-2587.
18. KELLER N, MOORE D, CARPER D, LONGWELL A: Increased corneal permeability induced by the dual effects of transient tear film acidification and exposure to benzalkonium chloride. Exp. Eye Res. (1980) 30(2):203-210.
19. GREEN K, TONJUM A: Influence of various agents on corneal permeability. Am. J. Ophthalmol. (1971) 72(5):897-905.
20. PFISTER RR, BURSTEIN N: The effects of ophthalmic drugs, vehicles, and preservatives on corneal epithelium: a scanning electron microscope study. Invest Ophthalmol. (1976) 15(4):246-259.
21. GASSET AR, ISHII Y, KAUFMAN HE, MILLER T: Cytotoxicity of ophthalmic preservatives. Am. J. Ophthalmol. (1974) 78(1):98-105.
22. CHAMPEAU EJ, EDELHAUSER HF: The effect of ophthalmic preservatives on the ocular surface: conjunctival and corneal uptake and distribution of benzalkonium chloride and chlorhexidine digluconate. In: The Preocular Tear Film in Health, Disease and Contact Lens Wear. FJ. Holly (Ed.), Dry eye Institute, Inc., Lubbock, TX, USA (1986):292-302.
23. AHMED I, PATTON TF: Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Invest. Ophthalmol. Vis. Sci. (1985) 26(4):584-587.
24. AHMED I, GOKHALE RD, SHAH MV, PATTON TF: Physicochemical determinants of drug diffusion across the conjunctiva, sclera, and cornea. J. Pharm. Sci. (1987) 76(8):583-586.
25. SASAKI H, IGARASHI Y, NAGANO T, NISHIDA K, NAKAMURA J: Different effects of absorption promoters on corneal and conjunctival penetration of ophthalmic beta-blockers. Pharm. Res. (1995) 12(8):1146-1150.
26. OLTHOFF CM, SCHOUTEN JS, VAN DE BORNE BW, WEBERS CA: Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology (2005) 112(6):953-961.
27. VAN SANTVLIET L, LUDWIG A: Determinants of eye drop size. Surv. Ophthalmol. (2004) 49(2):197-213.
28. HEPSEN IF, YILDIRIM Z, YILMAZ H, KOTUK M: Preventive effect of lacrimal occlusion on topical timolol-induced bronchoconstriction in asthmatics. Clin. Experiment Ophthalmol. (2004) 32(6):597-602.
29. GRASS GM, WOOD RW, ROBINSON JR: Effects of calcium chelating agents on corneal permeability. Invest. Ophthalmol. Vis. Sci. (1985) 26(1):110-113.
30. KAUR IP, SMITHA R: Penetration enhancers and ocular bioadhesives: two new avenues for ophthalmicdrug delivery. Drug Dev. Ind. Pharm. (2002) 28(4):353-369.
31. SARRAF D, LEE DA: The role of iontophoresis in ocular drug delivery. J. Ocul. Pharmacol. (1994) 10(1):69-81.
32. HALHAL M, RENARD G, COURTOIS Y, BENEZRA D, BEHAR-COHEN F. Iontophoresis: from the lab to the bed side. Exp. Eye Res. (2004) 78(3):751-757.
33. ROOTMAN DS, JANTZEN JA, GONZALEZ JR, FISCHER MJ, BEUERMAN R, HILL JM: Pharmacokinetics and safety of transcorneal iontophoresis of tobramycin in the rabbit. Invest. Ophthalmol. Vis. Sci. (1988) 29(9):1397-401.
34. NAVEH N, MUCHTAR S, BENITA S: Pilocarpine incorporated into a submicron emulsion vehicle causes an unexpectedly prolonged ocular hypotensive effect in rabbits. J. Ocul. Pharmacol. (1994) 10(3):509-520.
35. CALVO P, ALONSO MJ, VILA-JATO JL, ROBINSON JR: Improved ocular bioavailability of indomethacin by novel ocular drug carriers. J. Pharm. Pharmacol. (1996) 48(11):1147-1152.
36. BEILIN M, NAR-ILAN A, AMSELEM S et al.: Ocular retention time of submicron emulsion (SME) and the mitotic response to pilocarpine delivered in SME. Invest. Ophthalmol. Vis. Sci. (1994) 36:S166:S805.
37. PATTON TF, ROBINSON JR: Ocular evaluation of polyvinyl alcohol vehicle in rabbits. J. Pharm. Sci. (1975) 64(8):1312-1316.
38. SAETONE MF, GIANNACCINI B, RAVECCA S, LA MARCA F, TOTA G: Polymer effects on ocular bioavailability: the influence of different liquid vehicles on the mydriatic response of tropicamide in humans and rabbits. Int. J. Pharm. (1984) 931:1165-1168.
39. GENTA I, CONTI B, PERUGINI P, PAVANETTO F, SPADARO A, PUGLISI G: Bioadhesive microspheres for ophthalmic administration of acyclovir. J. Pharm. Pharmacol. (1997) 49(8):737-742.
40. DI COLO G, ZAMBITO Y, BURGALASSI S, SERAFINI A, SAETTONE MF: Effect of chitosan on in vitro release and ocular delivery of ofloxacin from erodible inserts based on poly(ethylene oxide). Int. J. Pharm. (2002) 248(1-2):115-122.
41. TICHO U, BLUMENTHAL M, ZONIS S, GAL A, BLANK I, MAZOR ZW: A clinical trial with Piloplex - a new long-acting pilocarpine compound: preliminary report. Ann. Ophthalmol. (1979) 11(4):555-561.
42. ROZIERE A, MAZUEL C, GROVE J, PLAZONNET B: Gtelrite: a novel ion activated, in situ gelling polymer for ophthalmic vehicles: effect on bioavailability of timolol. Int. J. Pharm. (1989) 57:163-168.
43. IBRAHIM H, GURNY R, BURI P, GROVE J, ROZIER A, PLAZONNET B: Ocular bioavailability of pilocarpine from phase transition latex system triggered by pH. Eur. J. Drug Metab. Pharmacokinet. (1990) 15(Suppl.):206.
44. MILLER SC, DONOVAN MD: Effect of poloxamer 407 gel on the motic activity of pilocarpine nitrate in rabbits. Int. J. Pharm. (1982) 12:147-152.
45. MACOUL KL, PAVAN-LANGSTON D: Pilocarpine ocusert system for sustained control of ocular hypertension. Arch. Ophthalmol. (1975) 93(8):587-590.
46. BUCOLO C, MANGIAFICO S, SPADARO A: Methylprednisolone delivery by Hyalobend corneal shields and its effects on rabbit ocular inflammation. J. Ocul. Pharmacol. Ther. (1996) 12(2):141-149.
47. EBRAHIM S, PEYMAN GA, LEE PJ: Applications of liposomes in ophthalmology. Surv. Ophthalmol. (2005) 50(2):167-182.
48. VAN DER VEEN G, BROERSMA L, DIJKSTRA CD, VAN ROOIJEN N, VAN RIJ G, VAN DER GAAG R: Prevention of corneal allograft rejection in rats treated with subconjunctival injections of liposomes containing dichloromethylene diphosphonate. Invest. Ophthalmol. Vis. Sci. (1994) 35(9):3505-3515.
49. SCHMIDT-ERFURTH U, HASAN T, SCHOMACKER K, FLOTTE T, BIRNGRUBER R: In vivo uptake of liposomal benzoporphyrin derivative and photothrombosis in experimental corneal neovascularization. Lasers Surg. Med. (1995) 17(2):178-188.
50. KHOOBEHI B, PEYMAN GA, MCTURNAN WG, NIESMAN MR, MAGIN RL: Externally triggered release of dye and drugs from liposomes into the eye. An in vitro and in vivo study. Ophthalmology (1988) 95(7):950-955.
51. IRACHE JM, MERODIO M, ARNEDO A, CAMAPANERO MA, MIRSHAHI M, ESPUELAS S: Albumin nanoparticles for the intravitreal delivery of anticytomegaloviral drugs. Mini Rev. Med. Chem. (2005) 5(3):293-305.
52. DE CAMPOS AM, SANCHEZ A, ALONSO MJ: Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int. J. Pharm. (2001) 224(1-2):159-168.
53. DE CAMPOS AM, DIEBOLD Y, CARVALHO EL, SANCHEZ A, ALONSO MJ: Chitosan nanoparticles as new ocular drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity. Pharm. Res. (2004) 21(5):803-810.
54. BUCOLO C, MALTESE A, MAUGERI F, BUSA B, PUGLISI G, PIGNATELLO R: Eudragit RL100 nanoparticle system for the ophthalmic delivery of cloricromene. J. Pharm. Pharmacol. (2004) 56(7):841-846.
55. PIGNATELLO R, BUCOLO C, PUGLISI G: Ocular tolerability of Eudragit RS100 and RL100 nanosuspensions as carriers for ophthalmic controlled drug delivery. J. Pharm. Sci. (2002) 91(12):2636-2641.
56. BAUM J, BARZA M: Topical versus subconjunctival treatment of bacterial corneal ulcers. Ophthalmology (1983) 90(2):162-168.
57. JAIN MR, GOYAL M, JAIN V: Ocular penetration of subconjunctivally injected gentamicin, sisomicin and cephaloridine. Jpn. J. Ophthalmol. (1988) 32(4):392-400.
58. KOMPELLA UB, BANDI N, AYALASOMAYAJULA SP: Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest. Ophthalmol. Vis. Sci. (2003) 44(3):1192-201.
59. VAN QUILL KR, DIOGUARDI PK, TONG CT et al.: Subconjunctival carboplatin in fibrin sealant in the treatment of transgenic murine retinoblastoma. Ophthalmology (2005) 112(6):1151-1158.
60. GILBERT JA, SIMPSON AE, RUDNICK DE, GEROSKI DH, AABERG TM Jr, EDELHAUSER HF: Transscleral permeability and intraocular concentrations of cisplatin from a collagen matrix. J. Control. Release (2003) 89(3):409-417.
61. MEREDITH TA: Antibiotics and antifungals. In: Textbook of Ocular Pharmacology. TJ Zimmerman (Ed.), Lippincott-Raven Publishers, Philadelphia, PA, USA (1997):363-385.
62. HARIPRASAD SM, MIELER WF, HOLZ ER: Vitreous and aqueous penetration of orally administered gatifloxacin in humans. Arch. Ophthalmol. (2003) 121(3):345-350.
63. OZTURK F, KORTUNAY S, KURT E, ILKER SS, BASCI NE, BOZKURT A: Penetration of topical and oral ciprofloxacin into the aqueous and vitreous humor in inflamed eyes. Retina (1999) 19(3):218-222.
64. OZTURK F, KORTUNAY S, KURT E et al.: Effects of trauma and infection on ciprofloxacin levels in the vitreous cavity. Retina (1999) 19(2):127-130.
65. TALWAR D, KULKARNI A, AZAD R et al.: Intraocular ciprofloxacin levels after oral administration in silicone oil-filled eyes. Invest. Ophthalmol. Vis. Sci. (2003) 44(2):505-509.
66. MARTIN DF, FICKER LA, AGUILAR HA, GARDNER SK, WILSON LA, MEREDITH TA: Vitreous cefazolin levels after intravenous injection. Effects of inflammation,repeated antibiotic doses, and surgery. Arch. Ophthalmol. (1990) 108(3):411-414.
67. OLSEN TW, AABERG SY, GEROSKI DH, EDELHAUSER HF: Human sclera: thickness and surface area. Am. J. Ophthalmol. (1998) 125(2):237-241.
68. DOANE MG, JENSEN AD, DOHLMAN CH: Penetration routes of topically applied eye medications. Am. J. Ophthalmol. (1978) 85(3):383-386.
69. RAGHAVA S, HAMMOND M, KOMPELLA UB: Periocular routes for retinal drug delivery. Expert Opin. Drug Del. (2004) 1(1)99-114.
70. BILL A: Movement of albumin and dextran throught the sclera. Arch. Ophthalmol. (1965) 74:248-252.
71. OLSEN TW, EDELHAUSER HF, LIM JI, GEROSKI DH: Human scleral permeability. Effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest. Ophthalmol. Vis. Sci. (1995) 36(9):1893-903.
72. RUDNICK DE, NOONAN JS, GEROSKI DH, PRAUSNITZ MR, EDELHAUSER HF: The effect of intraocular pressure on human and rabbit scleral permeability. Invest. Ophthalmol. Vis. Sci. (1999) 40(12):3054-3058.
73. LEE SB, GEROSKI DH, PRAUSNITZ MR, EDELHAUSER HF: Drug delivery through the sclera: effects of thickness, hydration, and sustained release systems. Exp. Eye Res. (2004) 78(3):599-607.
74. KAO JC, GEROSKI DH, EDELHAUSER HF: Transscleral permeability of fluorescent-labeled antibiotics. J. Ocul. Pharmacol. Ther. (2005) 21(1):1-10.
75. MORA P, EPERON S, FELT-BAEYENS O, GURNY R, SAGODIRA S, BRETON P, GUEXgCROSIER Y: Trans-scleral diffusion of triamcinolone acetonide. Curr. Eye Res. (2005) 30(5):355-361.
76. SHULER RK JR, DIOGUARDI PK, HENJY C, NICKERSON JM, CRUYSBERG LP, EDELHAUSER HF: Scleral permeability of a small, single-stranded oligonucleotide. J. Ocul. Pharmacol. Ther. (2004) 20(2):159-168.
77. WEIJTENS O, FERON EJ, SCHOEMAKER RC et al.: High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. Am. J. Ophthalmol. (1999) 128(2):192-197.
78. WEIJTENS O, VAN DER SLUIJS FA, SCHOEMAKER RC et al.: Peribulbar corticosteroid injection: vitreal and serum concentrations after dexamethasone disodium phosphate injection. Am. J. Qphthalmol. (1997) 123(3):358-363.
79. WEIJTENS O, SCHOEMAKER RC, LENTJES EG, ROMIJN FP, COHEN AF, VAN MEURS JC: Dexamethasone concentration in the subretinal fluid after a subconjunctival injection, a peribulbar injection, or an oral dose. Ophthalmology (2000) 107(10):1932-1938.
80. LEE TW, ROBINSON JR: Drug delivery to the posterior segment of the eye: some insights on the penetration pathways after subconjunctival injection. J. Ocul. Pharmacol. Ther. (2001) 17(6):565-572.
81. BALASUBRAMANIAM J, KUMAR MT, PANDIT JK, KANT S: Gellan-based scleral implants of indomethacin: in vitro and in vivo evaluation. Drug Deliv. (2004) 11(6):371-379.
82. OKABE K, KIMURA H, OKABE J, KATO A, KUNOU N, OGURA Y: Intraocular tissue distribution of betamethasone after intrascleral administration using a non-biodegradable sustained drug delivery device. Invest. Ophthalmol. Vis. Sci. (2003) 44(6):2702-2707.
83. CARRASQUILLO KG, RICKER JA, RIGAS IK, MILLER JW, GRAGOUDAS ES, ADAMIS AP: Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-coglycolic)acid microspheres. Invest. Ophthalmol. Vis. Sci. (2003) 44(1):290-299.
84. SAISHIN Y, SILVA RL, SAISHIN Y et al.: Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model. Invest. Ophthalmol. Vis. Sci. (2003) 44(11):4989-4993.
85. KOMPELLA UB, BANDI N, AYALASOMAYAJULA SP: Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest. Ophthalmol. Vis. Sci. (2003) 44(3):1192-201.
86. OLSEN TW, EDELHAUSER HF, LIM JI, GEROSKI DH: Human scleral permeability. Effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest. Ophthalmol. Vis. Sci. (1995) 36(9):1893-903.
87. WEINREB RN, LINDSEY JD, MARCHENKO G, MARCHENKO N, ANGERT M, STRONGIN A: Prostaglandin FP agonists alter metalloproteinase gene expression in sclera. Invest. Ophthalmol. Vis. Sci. (2004) 45(12):4368-4677.
88. WEINREB RN: Enhancement of scleral macromolecular permeability with Prostaglandins. Trans. Am. Ophthalmol. Soc. (2001) 99:319-343.
89. KIM JW, LINDSEY JD, WANG N, WEINREB RN: Increased human scleral permeability with prostaglandin exposure. Invest. Ophthalmol. Vis. Sci. (2001) 42(7):1514-1521.
90. OKABE K, KIMURA H, OKABE J et al.: Effect of benzalkonium chloride on transscleral drug delivery. Invest. Ophthalmol. Vis. Sci. (2005) 46(2):703-708.
91. LAM TT, FU J, TSO MO: A histopathological study of retinal lesions inflicted by transcleral iontophoresis. Graefes Arch. Clin. Exp. Ophthalmol. (1991) 229:389-394.
92. SANTOIANNI P, NINO M, CALABRO G: Intradermal drug delivery by low-frequency sonophoresis (25 kHz). Dermatol. Online J. (2004) 10(2):24.
93. WESTFALL AC, OSBORN A, KUHL D, BENZ MS, MIELER WF, HOLZ ER: Acute endophthalmitis incidence: intravitreal triamcinolone. Arch. Ophthalmol. (2005) 123(8):1075-1077.
94. OZKIRIS A, ERKILIC K: Complications of intravitreal injection of triamcinolone acetonide. Can. J. Ophthalmol. (2005) 40(1):63-68.
95. MOSHFEGHI DM, KAISER PK, SCOTT IU et al.: Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am. J. Ophthalmol. (2003) 136(5):791-796.
96. MISHIMA S: Clinical pharmacokinetics of the eye. Proctor lecture. Invest. Ophthalmol. Vis. Sci. (1981) 21(4):504-541.
97. XU J, HEYS JJ, BAROCAS VH, RANDOLPH TW: Permeability and diffusion in vitreous humor: implications for drug delivery. Pharm. Res. (2000) 17(6):664-669.
98. MAURICE D: Review: practical issues in intravitreal drug delivery. J. Ocul. Pharmacol. Ther. (2001) 17(4):393-401.
99. MARMOR MF, NEGI A, MAURICE DM: Kinetics of macromolecules injected into the subretinal space. Exp. Eye Res. (1985) 40(5):687-696.
100. BARZA M, KANE A, BAUM J: Pharmacokinetics of intravitreal carbenicillin, cefazolin, and gentamicin in rhesus monkeys. Invest. Ophthalmol. Vis. Sci. (1983) 24(12):1602-1606.
101. FICKER L, MEREDITH TA, GARDNERS, WILSON LA: Cefazolin levels after intravitreal injection. Effects of inflammation and surgery. Invest. Ophthalmol. Vis. Sci. (1990) 31(3):502-505.
102. COSTABILE BS: Treatment of cytomegalovirus retinitis with intraocular implants.AORN J. (1998) 67(2):356-360.
103. JAFFE GJ, MCCALLUM RM, BRANCHAUD B, SKALAK C, BUTUNER Z, ASHTON P: Long-term follow-up results of a pilot trial of a fluocinolone acetonideimplant to treat posterior uveitis. Ophthalmology (2005) 112(7):1192-1198.
104. JAFFE GJ, YANG CS, WANG XC, COUSINS SW, GALLEMORE RP, ASHTON P: Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis. Ophthalmology (1998) 105(1):46-56.
105. HAYREH SS: Posterior drainage of the intraocular fluid from the vitreous. Exp. Eye Res. (1966) 5:123-144.
106. ALGVERE P, BILL A: Drainage of microspheres and RBCs from the vitreous of aphakic and phakic eyes. Arch. Ophthalmol.(1979) 97:1333-1336.
107. D'AMICO DJ, CASPERS-VELU L, LIBERT J et al.: Comparative toxicity of intravitreal aminoglycoside antibiotics. Am. J. Ophthalmol. (1985) 100(2):264-275.
108. SUTTER FK, GILLIES MC: Pseudo-endophthalmitis after intravitreal injection of triamcinolone. Br. J. Ophthalmol. (2003) 87(8):972-974.
109. BROWN WJ, BUIST NR, GIPSON HT, HUSTON RK, KENNAWAY NG: Fatal benzyl alcohol poisoning in a neonatal intensive care unit. Lancet (1982) 1(8283):1250.
110. GARCIA-ARUMI J, BOIXADERA A, GIRALT J et al.: Comparison of different techniques for purification of triamcinolone acetonide suspension for intravitreal use. Br. J. Ophthalmol. (2005) 89(9):1112-1114.
111. MASUDA I, MATSUO T, YASUDA T, MATSUO N: Gene transfer with liposomes to the intraocular tissues by different routes of administration. Invest. Ophthalmol. Vis. Sci. (1996) 37(9):1914-1920.
112. TAKAHASHI T, NAKAMURA T, HAYASHI A et al.: Inhibition of experimental choroidal neovascularization by overexpression of tissue inhibitor of metalloproteinases-3 in retinal pigment epithelium cells. Am. J. Ophthalmol. (2000) 130(6):774-781.
113. ZEIMER R, GOLDBERG MF: Novel ophthalmic therapeutic modalities based on noninvasive light-targeted drug delivery to the posterior pole of the eye. Adv. Drug Deliv. Rev. (2001) 52(1):49-61.
114. KURZ D, CIULLA TA: Novel approaches for retinal drug delivery. Ophthalmol. Clin. North Am. (2002) 15(3):405-410.
115. YASUKAWA T, KIMURA H, TABATA Y, OGURA Y: Biodegradable scleral plugs for vitreoretinal drug delivery. Adv. Drug Deliv. Rev. (2001) 52(1):25-36.
116. BERGER AS, CHENG CK, PEARSON PA et al.: Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. (1996) 37(11):2318-2325.